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Abstract
Survival and quality of life in head and neck cancer are directly linked
to the size of the primary tumor at first detection. In order to achieve
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prevention,whichisearlydetectionofmalignantlesionsatasmallsize,
have to be improved. So far, there is not only a lack in the necessary
infrastructurenotonlyinGermany,butratherworldwide,butadditionally
the techniques developed so far for early detection have a significance
and specificity too low as to warrant safe implementation for screening
programs.However, the advancementsrecentlyachieved in endoscopy
and in quantitative analysis of hypocellular specimens open new per-
spectivesforsecondaryprevention.Chromoendoscopyandnarrowband
imaging (NBI) pinpoint suspicious lesions more easily, confocal endo-
microscopy and optical coherence tomography obtain optical sections
through those lesions, and hyperspectral imaging classifies lesions ac-
cordingtocharacteristicspectralsignatures.Thesetechniquestherefore
obtain optical biopsies. Once a “bloody” biopsy has been taken, the
plethora of parameters that can be quantified objectively has been in-
creased and could be the basis for an objective and quantitative classi-
fication of epithelial lesions (multiparametric cytometry, quantitative
histology). Finally, cytomics and proteomics approaches, and lab-on-
the-chiptechnologymighthelptoidentifypatientsathigh-risk.Sensitivity
andspecificityoftheseapproacheshavetobevalidated,yet,andsome
techniques have to be adapted for the specific conditions for early de-
tectionofheadandneckcancer. Onthisbackgroundithastobestated
that it is still a long way to go until a population based screening for
head and neck cancer is available. The recent results of screening for
canceroftheprostateandbreasthighlightthedifficultiesimplemented
in such a task.
Keywords: quantitative histology, human cytome project, hyperspectral
imaging, optical coherence tomography
1 Introduction
RecentdataoftheRobertKoch-Instituteshowanincrease
ofnewlydiagnosedcancerinGermanyto425,000cases
in 2002 equaling 8% or 30,000 more cases than 2000.
About220,000patientshavediedofcancerin2002[1].
TheDRG-statistic2006showsthat82,401patientshave
been treated as in-patients with ICD-codes C00–C14,
C30–C33, C76, and C77 in German hospitals [2]. This
sums up all cases from initial staging to curative treat-
ment and palliative care.
This highlights that oncological prevention is a task for
the entire society. The aim of prevention is to reduce the
number of patients affected by cancer or succumbing to
cancertooearly.Thisconceptisbasedonprimarypreven-
tion(preventingtheinitiationofcancer)andonsecondary
prevention (early detection of cancer). An estimate of
50%mightbepreventedorcuredbyprimaryandsecond-
ary prevention [1]. However, the value of prevention is
under discussion and only 1% of the resources of the
general health insurance in Germany are spent on pre-
vention [3]. It certainly is wrong that prevention in prin-
ciple is always safer and cheaper than treatment [4].
Implementingscreeningandpreventionwithoutthorough
validationintopopulationbasedprogramsisproblematic,
and the only screening program introduced so far (for
breast cancer) is discussed contrarily [5]. Screening
mammography for women aged 50 to 69 years reduces
mortality of this age group by 15%: out of 2,000 women
at this age 1 woman is saved from breast cancer death
in a 10 years period; but 10 women get overdiagnosis or
overtherapy, and 20% of women get at least 1 false-
positivereportwithin10years[6].Mostrelevantarefalse-
negative cases, such called interval-carcinoma which go
undetectedforalongtimesincetheywerenon-pathologic-
al at screening. However, this phenomenon is hard to
pinpoint in numbers. For other malignancies which are
under discussion for screening (malignant melanoma,
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effects.Ontop,thereisnogenerallyacceptedhistological
classification for epithelial neoplastic lesions, as it can
also be observed in malignant melanoma where even
experts hardly come to the same histological diagnosis
[7].
ReactingtotheunsatisfiedsituationinGermanymembers
oftheworkinggroup“Krebsepidemiologie”oftheGerman
Society ofEpidemiologyhave publisheda papertogether
withtheGermanCochraneCentre[8].Theyconcludethat
Germany completely lacks a sufficient infrastructure for
conducting and evaluating of screening programs with
the only exemption of breast cancer screening. In that
case for the first time a specific test is applied centrally
andtheprocessqualityismonitored.Themostimportant
aimofanyscreeningultimatelyisareductionofmortality
without screening side effects. In contrast of present
“opportunistic” screening the targeted population of a
true screening is healthy and has no symptoms yet. The
goals for such a screening are: 1. reduction of incidence;
2.reductionofmortality;3.reductionofoverallmortality;
and4.improvementofqualityoflife.Ineffectivescreening
just allows making the correct diagnosis earlier without
alteringthecourseofthedisease.Truenetgaininlifetime
can only be achieved by shifting death to later periods of
life yielding to an overall longer life with known diagnosis
(Figure 1). However, even optimal screening programs
bear the risk of overdiagnosis and -therapy: minimal in-
vasive and in situ carcinomas are detected and treated
which would have never been clinically relevant in the
patient’s lifetime.
In addition, the public discussion focuses on the cost
factor. According to the Fritz-Beske-Institute the overall
costforthehealthsystemwillincreasefrom218billiards
today to 270 billiards Euro by the year of 2050 only due
to the increase of expected life time. The cost per year
per inhabitant in professional productive age for the
treatment of cancer will therefore increase from 172.- €
in 2008 to 280.- € in 2050. This calculation does not in-
cludeextracostsforinnovativediagnosticsandtherapeut-
ics. But just due to a lack of competent health care pro-
fessionalsa hidden rationalizationwill occur[9]. This will
yield to a health care collapse [10].
Up to 30% of cancer is estimated to be associated with
avoidable risk factors (smoking, alcohol, occupational
toxics,butalsoobesity,lossofmobility)[1];nevertheless,
so far the positive influence of a “healthy” lifestyle on
cardiovascular disease, colon and breast cancer could
not be proven [11], [12], [13]. Substitution with specific
nutritientswhichseemtobesensibleatfirstsightturned
outtobedevastatingonacloserlook:additionofcalcium
andvitaminDdidnotreducethenumberoffracturesbut
insteadincreasethenumberofnephroliths[14],andthe
“preventive” addition of estrogens and gestagens in
postmenopausal women lead to significant additional
health problems and massive health costs [15]. This
underlines the necessary thorough evaluation of any
screeningprogramtoprovethatthereisapositiveoverall
cost-risk-ratio. The evidence must be clearly and object-
ively documented, and there must not be a negative
consequence for not attending a program.
As early as 1984 Steiner showed that patient groups at
high risk for head and neck cancer can be defined, that
an adequate screening method is available [16], that
endoscopy can be combined with cytology [17] albeit at
slightly higher costs [18]. However, an anachronistic
paradoxstillholdstrueunchanged:althoughcervixcancer
has lower incidence and mortality in that anatomical
location exfoliative cytology and PAP-staining are part of
the routine screening but an equivalent approach for
head and neck cancer is still absent. A colposcopic PAP-
swabseemstobemorereadilyacceptedthanalookinto
the oral cavity [19]. Indeed there is no high acceptance
for screening of head and neck cancer throughout the
population: even if directly invited in written form only
30–60%takepartinscreening;especiallysmokershave
a low compliance [20], [21].
This phenomenon can be explained by the concept of
cognitive dissonance [22], [23], [24]. According to that
concept every individual tries to avoid non-congruent
cognitive elements in order to reduce cognitive disson-
ance. Cognitive dissonance for example is produced by
the clash of the attitude “I like smoking” with the fact
“Smoking causes cancer”. In order to reduce this intrain-
dividual dissonance smokers fade the uncomfortable in-
formationout,thinkingthatitisnotrelevantforthemand
not realizing the warnings printed on the cigarette packs
[25]. Cognitive dissonance has direct influence on the
attitude and the acceptance of screening schemes [26].
Onthenationallevelscreeningforheadandneckcancer
has not been included into the national plan on “Early
DetectionofCancer”oftheDeutscheKrebshilfefollowing
a national hearing in 2005 [27]. Therefore it can be
claimed a great success to have head and neck cancer
includedintotheNationaleOnkologischePräventionskon-
ferenz2007inEssen[28].AccordingtotheRobert-Koch-
Institutethenumberofnewcasesoforalandpharyngeal
cancer in 2006 is 7,800 and 2,600 patients, and 2,800
and 450 for laryngeal cancer (male and female, resp.)
[29]. Including the cases of cancer of nose and
paranasal sinuses, salivary glands, and other rare cases
altogether 18–20,000 new head and neck cancer cases
peryearcanbeestimatedinGermany.TheDRG-statistics
of the Statistisches Bundesamt details the in-patient
cases in 2006 [2]: there have been 39,080 cases of
cancer of the lips, oral cavity, and pharynx (C00–C11,
C14), 9,296 cases of cancer of the hypopharynx (C12,
C13), and 15,108 cases of cancer of the larynx and
trachea (C32, C33). These cases have been associated
with a mean stay as an in-patient of 8–10 days [2]. It is
estimated that worldwide 615,000 new cases of head
and neck cancer occur per year with a strong male pre-
ponderance(10–15:1).However,therearestrongregion-
al differences in some anatomical sublocalisations [30].
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2 Risk factors
In order to prevent cancer or to detect it early potential
and known risk factors have to be evaluated. In general
and also for head and neck cancer the socioeconomic
status of the patient has impact on his or her treatment.
A retrospective analysis based in Georgia, USA, showed
thattheinsurancestatushadsignificantinfluenceonthe
survival of patients with head and neck cancer [31]. The
observed delay time in making the diagnosis is mainly
duetopatientfactorsbuttherearedifferentgapsreport-
ed depending on the anatomical sublocalisation ranging
from 5 to 19 weeks [32], [33]. In oral cavity and pharyn-
geal cancer the delay was worst in non-smokers, large
tumors, and singles [34].
2.1 Smoking
Tobaccosmokingisaknownriskfactorforheadandneck
cancer.TheHeidelbergercase-control-studyshowedthat
>30 pack years increase the risk for head and neck
cancer by the factor 4.8 [35], and >60 pack years by the
factor 23.4 [36]. This information is relevant in the con-
text of a study about smoking habits of the young in
Germany: for those aged 12–17 years the percentage of
smokers had a historical maximum in 1970 with 30%,
decreased to 20% in 1993, had another rise until 1997
to 28%, and from then on showed a decrease to recent
18% of which each 9% assign themselves as occasional
and permanent smokers, respectively [37]. In addition,
the novel trend of shisha-smoking has to be mentioned,
which14%nametobeconsumedatleastoncepermonth
without assigning it as smoking nor as dangerous.
2.2 Alcohol
Alcohol is another known risk factor for head and neck
cancer. The odds ratio ranges from 9.4 for 75 g ethanol
per day [35] and 11.7 for >100 g ethanol per day [38].
There is a controversy about a hypothesized influence of
the kind of alcohol consumed (wine vs. liquor etc.). How-
ever, there is a gender dependence: in females a con-
sumption of >30 g ethanol per day increases the relative
risk for head and neck cancerto 29; 40% of femalehead
and neck cancer patients consumed >30 g ethanol per
day [39]. In this group the amount of ethanol was lowest
incancerofthelipsandhighestinhypopharyngealcancer
[40].
Again,theattitudeoftheprospectivenewcancerpatients,
i.e. those now aged 12–17 years, has to be taken into
account. Unfortunately, in this context the headlines of
therainbowpresshavetobeverified:from2004to2007
the total amount of ethanol consumed per week by this
age group raised from 60 g to 71 g (male) and from 27
g to 29 g (female). Most alarming, such called binge-
drinking (consuming more than 5 alcoholic drinks in one
day) which is taken as an indicator for risky alcohol atti-
tude has increased overall from 23% to 25%, focusing
on 16–17 years old from 51% to shocking 63% [41].
Finally, the combination of both, smoking and drinking,
has the highest propagating effect on head and neck
cancer. This effect is over-additive and dose dependent.
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consumption of nicotine, and cancer of the oropharynx
and the larynx had the highest consumption of ethanol
[36]. The combined consumption of >75 g ethanol per
day and >30 pack years increase the odds ratio to 92
[35]. Asanadditionalriskfactoratleastforcancerofthe
oral cavity poor oral hygiene and dental status (>20
missingteeth)hasbeendocumented(oddsratio5.3and
3.4 respectively) [42].
2.3 Occupational toxics
Prof. Maier and his team have detailed various occupa-
tional poisons and showed the relative risk to develop
head and neck cancer associated with them: asbestos
8.7, cement 12.9, tar 6.6, and dyes/paints/solvents 2.3
(larynx) and 3.6 (oral cavity). The highest relative risk is
achieved by the combination of these poisons with
nicotine and ethanol [35], [43], [44], [45]. Another risk
factor is the exposition to polycyclic aromates which in-
creases the odds ratio for laryngeal cancer to 5.2 [46].
In conclusion, the group of blue-collar workers with addi-
tional high consumption of nicotine and ethanol can be
identified as a high risk group for head and neck cancer.
A special condition is the sinunasal adenocarcinoma. In
this case, the exposition to inhalable dust of hard woods
such as oak and beech carries a high risk for developing
this cancer. The time delay is up to 40 years [47]. In
Germany,itisarecognizedoccupationalriskandaccept-
edasoccupationaldisease(BK4203)withsome30new
cases per year (among some 70,000 employers). The
odds ratio for joiners is 2.96. A concentration of 3.5
mg/m³ is definitively dangerous [48] showing a strong
correlationespeciallyforthehistologicalsubtypeofintes-
tinal type [49].
2.4 HPV-Infection
Although there was a general stagnation or even slight
decreaseintheoverallincidenceworldwideforheadand
neck cancer in parallel to the changing smoking habits,
there was a marked increase for the incidence of oral
cavity, tongue, and oropharyngeal cancer in never-
smokers never-drinkers [50]. In this group, young men
withtonsilcancer,youngwomenwithtonguecancer,and
elderly women with cheek cancer are over-represented
[51].Severalriskfactorshavebeenidentified:>50%were
serological positive for HPV16, 45% were passive
smokers, 24% had occupational toxics in their history,
and30%hadgastroesophagealreflux[51].Togetherwith
other viral infections (HIV, HPV, HSV) there indeed is a
plethora of risk factors in this group [52], [53].
The recent discussion focuses on the role of HPV16 in
never-smokers never-drinkers [54]. zur Hausen is Nobel
laureateforhavingestablishedtheconceptofoncogenic
viral infection [55]. First reports of HPV-positive cancer
oftheoropharynxandlarynxdatebackto1985and1987
[56], [57]. In 2006, in Sweden a marked percentage in-
crease of tonsil cancer positive for HPV among all head
and neck cancer cases from 1970 to 2000 was reported
based on PCR on DNA-extracts from archived material
[58]. Now, the presence of HPV-infection is recognized
as a risk factor on its own for oropharyngeal cancer [59].
HPV-positivetonsilcancercanberatedasaclinicalentity
on its own [60], having a better prognosis than HPV-
negative cancer [61]. A metaanalysis of 60 publications
showed the prevalence for HPV-infection to be 25.9% for
all head and neck cancer, highest in oropharynx (35.6%)
and larynx (24.0%) and oral cavity cancer (23.5%). In
oropharynxin87%ofpositivecasesareHPV16,whereas
in hypopharynx and larynx a higher proportion of HPV18
is seen (17% vs. 38%) [62]. This is the basis for the dis-
cussionaboutvaccinatingyoungmalesagainstHPV,too.
2.5 Chemoprevention
The great hopes initially put into the concept of chemo-
preventionhavenotholdtrue.Itwasjustshowngenerally
that the intake of 80 g per day of vegetables and fruit
reduces the relative risk for head and neck cancer t0
0.91 and therefore can be assigned protective [63].
However, there is no single chemically identified sub-
stance yielding a preventive effect: 13-cis-retinoid acid
did not influence the rate of secondary malignancies, re-
currence, nor disease-free survival [64], and vitamine A
and N-acetylcystein alone or in combination for 2 years
hadnoinfluenceonoverallsurvival,disease-freesurvival,
nor recurrence [65].
3 Precursor lesions
Anyattemptofearlydetectionofcancerimpliesaconcept
about how cancer arises in general. As early as 1890
Hansemann observed asymmetrical nuclear divisions in
human cancer and discussed their relevance in the can-
cerogenesis [66]. This idea was reintroduced 25 years
laterbyBoveriwhowasthefirsttodescribechromosomes
[67] and realized that a multipolare spindle apparatus
yieldstoamisalignmentandmaldivisionofchromosomes
[68]. (For a detailed review of this historic background
please refer to [69]). The development of stochiometric
DNA-staining by Feulgen [70] and the construction of
microscopes with quantitative densitometers [71] later
on allowed to obtain the underlying quantitative data for
these phenomena. As early as 1956 DNA-aneuploidy in
malignant tumours was documented [72]. Casperson
was then first to normalize the DNA-ploidy of cells from
premalignant lesions using leukocytes as internal stand-
ard [73]. These analyses were repeated more recently in
detail in breast cancer showing an inverse correlation of
histologicaldifferentiationandthe numberof interphase
nuclei with DNA-aneuploidy (>4.5c) [74].
Beginning in the 1980s a confronting alternative theory
on the development of cancer has been developed. Ac-
cording to that theory cancer is caused by a stepwise
activation of oncogenes and deactivation of cancer sup-
pressorgenes[75].Thisconstructionissupportedbythe
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cinoma (HNPCC) and of familial adenomatosis polyposis
(FAP); however, these cases account for not more than
5% of all colon cancers, most cases are not hereditary
but sporadic. Actually, objective analyses and observa-
tions in human cancers are in contrast to this concept:
about 50% of all known carcinogens are not mutagenic
[76], oncogenes are not clonally expressed so that part
of the cancer cells in a given malignancy lack them [77],
manyoncogenesarenotexpressedinmanycancercells,
and instead of hypothesized 4–7 mutations [78] rather
thousands of genes are mutated in cancer cells [79].
Spontaneous mutations, however, are extremely rare
(10
-6 per mitosis) [80] yielding to just ONE in 10
10–10
28
human beings developing cancer taking the postulated
4–7 mutations as baseline! The supposed mutation of a
“mutator-gene” can be found only in few cancers [81]
and typically in late states [82]. Above of that, the
hereditary “mutator-gene” which is postulated for Xero-
dermapigmentosumdoesnotleadtoanincreaseofnon-
skin cancer in respective individuals [83].
Thesecontradictionsofthisconceptinitselfrecentlyhave
increased the interest in the prior hypothesis that an-
euploidy is rather the cause but not the consequence of
cancer [84], [85]. Duesberg has developed a convincing
conceptdescribingcarcinogenesisasachainreactionof
aneuploidisation [86], [87].
As a matter of fact, a “precursor” lesion is defined by the
clinical context. The WHO just states: “Precursor lesions
are defined as altered epithelium with a high likelihood
to develop into cancer”. Clinically in general leukoplakia,
erythroplakia, and chronic inflammation are seen, histo-
logically represented as dysplasia and atypia. However,
what exactly a dysplasia is seems to be highly variable
according to Barnes and coworkers: “The terminology of
these precursor lesions, however, is still evolving and no
singleclassificationhasbeenuniversallyaccepted”[88].
Histopathologicallyanumberofhistologicalandcytologic-
al criteria are described leading to the diagnosis “dys-
plasia”.Infact,alsothesecriteriadoallowneitheraclear
separation of hyperplasia on the one hand and early
dysplasia on the other hand nor a separation of several
grades of dysplasia. The only sure fact is that cancer can
develop from any grade of dysplasia and can even arise
from completely intact mucosa.
The corresponding theoretical concept for precursor le-
sions is represented by the term “intraepithelial neo-
plasia”(IEN)fornon-invasivemucosallesionswithgenetic
alterations, loss of control of cellular functions, and
phenotypic characteristics of invasive cancer, summing
up in a lesion with high likelihood to progress into an in-
vasive cancer [89].
In contrast, the terms leukoplakia and erythroplakia are
clinically defined and have no place in pathological diag-
noses [90]. Leukoplakia was first used by Schwimmer in
1877 [91] and nowadays is defined by the WHO as a
“white patch or plaque that cannot be characterized
clinically or pathologically as any other disease“ [92].
Erythroplakia was first used by Queyrat in 1911 [93] and
in analogy is defined by the WHO as a “red patch of the
mucous membrane which does not represent some spe-
cific ornonspecific inflammatory lesion“[94]. Allerythro-
plakias presumably will show histological signs of dys-
plasia, in 51% invasive carcinoma has been observed
and in 40% carcinoma in situ or “severe” dysplasia have
been seen; as a consequence, erythroplakias even more
than leukoplakias should trigger an intensive diagnostic
evaluation [95]. In any case, in mixed lesions the
eurythroplakia component has to be included into an in-
cisional biopsy [90].
The problem of severe intra- and interobserver variability
in histological and cytological diagnoses is increasingly
realized and discussed [95], [96]. The influence of this
variabilityonscreeningschemeswasestimated[97].For
head and neck cancer the interobserver agreement in
judging such called oral pre-malignant lesions has been
evaluated. Overall only a good agreement could be
achieved (κW=0.59) with further reduction in cases with
accompanying inflammation (κW=–0.10) although histo-
logical instead of cytological specimens were evaluated;
inaddition,alsotheanatomicalsiteandthewayofbiopsy
(incision vs. punch) showed some influence on the
agreement. Taking bivariate rating (carcinoma and car-
cinoma in situ versus less severe changes) did not im-
prove agreement (κW=0.39). Only in non-smokers a very
good agreement was achieved (κW=0.71) [98], [99].
Similar results were obtained in laryngeal lesions
(κW=0.32),bivariatecomparisonyieldingκW=0.52[100].
Inthemeantimeithasbeenrealizedthattheseproblems
are immanent to the histopathological analysis itself ac-
cording to Lessells et al.: “Histopathological diagnosis is
not carried out in an algorithmic process. Individual
pathologistshaveahighlytrainedvisualcortex,suchthat
within a few seconds of looking at a slide a number of
conclusions have been drawn and a diagnosis (at least
provisional) made. Obviously, individual pathologists are
programmedinslightlydifferentways,accountingforthe
individual variation seen in a linear spectrum of abnor-
mality such as dysplasia. Even if strict criteria were ap-
plied, it is unlikely that any improvement would be more
than marginal” [101]. This highlights the effect of
screening is influenced by reproducible and correct
diagnoses. Taking the variance of histology and even
more cytology into account it is first of all up to the clin-
ician to identify suspicious lesions. It is the clinician who
hastodecideonwhichlesioncanbeobservedandwhich
has to be biopsied as it is the case in the esophagus
[102].
4 Present state of early detection
The above notes lead to the conclusion that a true
screening for head and neck cancer cannot be achieved
within the near future. In the following the different at-
tempts for secondary prevention, i.e. the early detection
of invasive carcinoma and its precursors, will be outlined
according to the anatomical subsites.
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The oral cavity and the oropharynx are ideal for early de-
tectionduetotheirgoodaccessibilityforinspection.First
considerationsaboutearlydetectionandscreeningwere
published in 1969, 1974, and 1978 [103], [104], [105].
Nevertheless,uptodatethereisnoconsensusguideline
forscreeningofpremalignantorallesions[90].Sincethe
5-year-survival correlates directly to the state at first dia-
gnosis, early detection not only could improve the inci-
dence but also the survival. The continuing input into
patient information and the ongoing education of com-
munitybasedphysiciansanddentistsareequallyimport-
ant [106], [107].
In a recent review by the Cochrane Collaboration [108]
onlyonestudyfromIndiawhereoralcavitycancerismore
frequent[109]hadsufficientquality.Butduetomethodo-
logical deficits (e.g. no data about costs and risks) also
this study did not give evidence pro or con for screening
for oral cavity and oropharynx cancer by inspection with
or without optical tools. Nevertheless, these tools are
outlined in the following chapters.
4.1.1 Chromogen-aided visual inspection
For a long time it has been recognized that altered mu-
cosa shows a staining behavior with exogenous dyes dif-
ferent from that of normal mucosa. One of the early dyes
is toluidine-blue which was first described in 1952 for its
use as intravital dye [110]. The exact mechanism is still
notunderstood.Severalstudieshaveevaluateditsclinical
use but the high rate of false-positive lesions has shown
its limited use [111], [112]. Other dyes such as Bengal-
Rose are little better even when intensity of the staining
is compared with a standardized table [113].
Using pre-incubation of the mucosa with 1% acetic acid
the ViziLite™ system tries to improve the detection of
altered mucosa by blue light (490–510 nm). However,
independent studies in contrary show that neither the
number of detected lesions is increased nor the correla-
tiontohistologyimproved[114].Someinvestigatorsrated
the reflections of the blue light as disturbing [115]. This
system also has a high false-positive rate leading to a
number too high for routine use in screening and
prompting an unacceptable number of unnecessary
biopsies [116].
Inconclusion,allassaysbasedonexogenouschromogens
relyonahighclinicalexperienceoftheinvestigator[117].
4.1.2 Autofluorescence
The phenomenon of autofluorescence is another tissue
feature recognized for some time [118] and first de-
scribed as a useful tool during bronchoscopy in 1962
[119]. Since then autofluorecence has been established
asanintegralpartthroughouttheentireupperaerodigest-
ive tract [120], [121], [122], [123]. Sensitivity and spe-
cificity for the discrimination of normal mucosa and can-
cer has been quoted to be 91% and 86%, both better
than for examination with white light (75% and 43%, re-
spectively).
Autofluorescence can be modified by applying 5-amino-
levulinic acid (5-ALA) topically or systemically. While
altered mucosa shows a loss of autofluorescence, it ex-
hibits a gain of 5-ALA-induced fluorescence. The specific
accumulation of 5-ALA in tumor cells was first described
in 1966 [124]. The resulting protoporphyrin IX-fluores-
cence is used to detect cancer. Since the cells first have
to metabolize the 5-ALA there has to be a time gap of
1.5–3 hours until the investigation is possible [125],
[126]. For this technique, a sensitivity of 99% and a
specificity of 60% are quoted.
4.1.3 Molecular markers
Cells form altered mucosa can be analyzed extensively
bymoleculargeneticassays.Lossofheterocygocity(LOH)
can be used as a marker for genetic changes: LOH at 9p
and 3q has been found in dysplasias, and an additional
LOH at 4q, 8p, 11q, and 17p has been associated with
an increased risk for the development of cancer [127],
[128].
Another genetic change is an infection with HPV. In that
context HPV16-infection in non-smokers non-drinkers
plays a special role. HPV16 infection is associated with
a higher risk of head and neck cancer in both, smokers
and non-smokers. The proportion of tumor specimens
containing the genome of the virus, however, varies
between neglectible and 70% [59], [61], [129]. A study
comparingHPV-statusinbiopsiesandexfoliativecytology
from the same patient showed no correlation between
theboth:90%ofpatientsHPV-positiveinthebiopsywhere
negative in the exfoliative cytology [130].
Theanalysisofcytologicalparametersisgivenanincreas-
ing importance in the context of early detection of oral
cavity and oropharyngeal cancer. Their value will be fur-
ther increase by including the analysis of quantitative
parameters [131] (see 5.1).
4.2 Larynx
Classical screening for laryngeal cancer is based on the
subjective analysisof conventionalindirectlaryngoscopy
withorwithoutmagnification[16].Initially“opticalampli-
fiers” were used such as the topical application of toluid-
ine blue [132]. This dye, however, was last mentioned
fortopicalapplicationinthelarynxin1982;inthatstudy,
the comparison with histology in 272 cases showed a
sensitivity of 91% and a specificity of 52% [133].
4.2.1 Autofluorescence
The application of autofluorescence in the larynx was re-
ported first in 1995 [134]. Autofluorescence has been
shown to improve both, sensitivity and specificity, in rigid
and flexible endoscopy for the delineation of the borders
of altered mucosa (to 97% and 84–92%, respectively).
The presence of inflammation, scaring, and hyperkera-
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leadingtofalse-positiveandfalse-negativeresults[121],
[135], [136], [137], [138].
The use of 5-ALA has also been evaluated for laryngo-
scopy. Again, a gain in 5-ALA induced fluorescence has
been observed in laryngeal cancer [125], [139]. A first
trial of topical 5-ALA for photodynamic therapy in a pilot
study, however, has been disappointing [140].
4.3 Hypopharynx
Since early symptoms in hypopharyngeal carcinoma are
vague or absent and since prognosis depends on size at
first presentation as in any other region, early detection
ofcancerofthehypopharynxwouldbeespeciallyeffective
[141], [142], [143]. In 2006, 9,296 patients have been
treatedasin-patientsinGermanywiththediagnosesC12
or C13 (cancer of the pririform recessus or cancer of the
hypopharynx;forcomparison:C32–cancerofthelarynx:
14,656 cases) according to the DRG-statistics of the
Statistisches Bundesamt [2].
The odds to detect hypopharyngeal cancer at an early
stage are best for patients who already had a carcinoma
of the upper aerodigestive tract or of the esophagus in
their history. This risk group has a substantial benefit
from routine endoscopies even if no symptoms are
present. The proportion of second primaries of the hypo-
pharynxin stageI + II versusstageIII + IV canbe dramat-
ically increased: from 22:78 without routine endoscopy
to 90:10 with routine endoscopy. As a consequence,
radical therapy with larynx preservation was possible in
79.4% with routine endoscopy as compared to 45.5%
without routine endoscopy [144].
4.4 Salivary glands
Tumors of the salivary glands have an especially broad
histological spectrum. Accordingly, the complex classifi-
cation has been revised several times [88]. For this
reason the data for some entities are insufficient. The
overall incidence for malignant salivary gland tumors is
0.4–2.6/100,000.Themostcommonmalignantsalivary
glandtumorseemstobethemucoepidermoidcarcinoma
[~50%ofcases),adenoidcysticcarcinomaragingsecond.
Theincidenceincreaseswithageculminatingaroundthe
age of 70. Males have a slight preponderance [145].
A known risk factor for malignant salivary gland tumors
is ionizing radiation (by the atom bomb [146] or by radio-
therapy [147] or by J131 e.g. as part of treatment for
thyroid disease [148]). Electromagnetic radiation of mo-
bile phones has no demonstrable negative effect [149].
Known occupational risk factors are nickel, chrome, as-
bestos,andcementdust,andingredientsusedinrubber
production [150], [151], [152]. Also hair dressers were
shown to be at increased risk [153]. Exceptionally there
is no increased risk for malignant salivary gland tumors
associated with smoking and drinking [154].
As a consequence there is only a small populationat risk
that can be defined as a target group for screening. In
2006, there have been 2,457 patients treated as in-pa-
tients in Germany with the diagnosis C07 or C08 (cancer
of the parotid gland or of other salivary glands of the
head)accordingtotheDRG-statisticsoftheStatistisches
Bundesamt [2].
4.4.1 Fine-needle aspiration biopsies
Fine-needle aspiration biopsy (FNAB) has been long es-
tablished as part of the diagnostic work-up for salivary
gland tumors and can in principle be used as a tool for
screening schemes [155], [156], [157], [158], [159].
These studies report false-positive and false-negative
results in 1–14% of cases. The correct diagnosis was
madein81–98%ofcases.Schröderetal.haveevaluated
the use of FNABs in the work-up of parotid gland tumors
in 2000 [160]. They did not see seeding of tumor cells
along the biopsy canal leading to satellite metastases or
any other relevant complication. Retrospectively, only
284 specimens out of 336 had been sufficient for
pathology due to the presence of tissue fragments; with
these 284 specimens, sensitivity was 93.1% and spe-
cificity was 99.2%. Those cases where only single cells
but no tissue fragments were obtained by FNAB were
scored“inadequate”.Obviously,conventional“cyto”patho-
logy is rather some kind of “microhisto”pathology. For
true cytopathology, i.e. the analysis of single cells,
quantitativeandobjectiveassaysareavailable(see5.1).
4.4.2 Ploidy
Up to recently the DNA-ploidy could only be determined
from freshly resected tumor tissue. Using flow cytometry
DNA-aneuploidy could be found in 24–28% of the malig-
nant tumors, and all histologically benign tumors were
DNA-diploid [161], [162]. The drawback of this method
is that the tumor first has to be resected before tissue
can be taken in order to obtain single cells for flow cyto-
metry. Consequently, this test cannot be used for
screening or preoperative analysis. As a matter of fact,
however, the analysis of DNA-ploidy has been shown to
bebeneficialaspartofthediagnosticwork-upofsalivary
gland tumors. For example, this test was able to identify
acarcinomaexpleomorphicadenomathatwasundetect-
ed by routine histology [163].
4.5 Second primaries and recurrences
The concept of field cancerisation was first published by
Slaughter et al. in 1953 following their observation that
headandneckcarcinomasingeneralhavearatherlateral
spread as compared to their vertical dimension and that
there is always surrounding mucosa which also shows
alterations to some extent [164]. This is also highlighted
byanecdoticreportsofsynchronousmultiplecarcinomas
of the same anatomical sublocalization [165]. Recently,
the respective molecular changes have been shown
[166]. The common criteria for a “second primary” have
beendefinedin1932[167]:tumorshavetohaveaclear,
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ametastasishastobeexcluded.Ratherarbitraryalateral
gapbetweenthetwolesionsof2.5cmandatimeinterval
of 3 years has been defined. In any case, patients with a
newly diagnosed head and neck cancer or a positive
history are at high risk to develop a second primary and
should be thoroughly investigated as well initially at first
presentation and during follow-up in order to detect a
second primary in the entire upper aerodigestive tract.
The rate of second primaries ranges from 9 to 19%;
41–46%aresynchronousand54–59%aremetachronous
[168], [169], [170], [171]. Using panendoscopy up to
85%ofsynchronousand67%ofmetachronoussecondary
primaries can be detected [172].
Whereas recurrence occurs within the first 3 years,
second primaries show an unchanged incidence beyond
the 5th year [168]. For laryngeal cancer, a population
basedstudyon20,074patientsshowedasecondprimary
in 3,533 cases (=17.6%); the cumulative risk was 26%
at10yearsand47%at20years.Treatmentwithradiation
therapy increased the risk to develop a second primary
especially in those patients who survived the 5th year
[173]. In general, a second primary is correlated with a
poor survival: the median survival is approximately 25
months [174].
The paradoxical late adverse effect of radiation therapy
in terms of inducting a second primary has been first
describedbyH.Glanzasearlyas1976[175].Sincethen,
the cancerogenic effect of low ionizing radiation doses
has been well documented [147], [173], [176]. On that
background, there is an additional risk to develop a
secondprimaryforpatientswithaheadandneckcancer:
the cancerogenic effect of radiation therapy. Especially
patientswithalowstagefirstprimaryshouldbenefitfrom
intensive follow-up since they have good chances for
curative treatment of the second primary, too. Extensive
surgerywithreconstructionbymicrovascularreanastom-
ised flaps had no influence on the risk to develop a
second primary [177].
4.5.1 Endoscopy
Repeatedendoscopyboth,asrigidhypopharyngo-laryngo-
esophagoscopy or as flexible videoesophagoscopy, are
a standard that can be offered to patients with head and
neck cancer and with esophageal cancer [178], [179],
[180].Thehighestbenefitisseenforpatientswithasmall
first primary: in T1-T2 carcinoma of the oral cavity, the
time gap from the end of the initial therapy to the detec-
tion of a second primary was beyond 60 months in 23%
of cases [181]. The survival time was significantly in-
creased in patients who underwent routine endoscopies
as compared to patients with disease-triggered endos-
copies from 32 months to 58 months [182].
4.5.2 “Tumormarker”
Inareviewoncirculatingtumormakersofheadandneck
cancer in 1994, not a single marker or a combination of
several markers had a level of sensitivity or specificity
high enough to justify its use as a “tumor marker”. If at
all some use for monitoring of therapy seemed helpful
[183].Thisjudgmentwasunchangedbytwolaterreports
which included molecular parameters [184], [185]. Out
of the proteins Cyfra21-1, SCC- and TPS-antigen
(squamouscellcarcinomaantigenandtissue-polypeptide
specific antigen, resp.) Cyfra21-1 seems to be adequate
to detect a recurrence or a second primary (sensitivity
96%, specificity 87%) [186], [187], [188]. Indeed, the
failure to define a single parameter or a combination of
markers predictive for head and neck cancer is due to
the fact that this group of malignancies has a wide
spectrum of molecular genetic changes represented by
the diverse histopathologic findings [189].
4.5.3 PET-CT
Since its introduction as fused PET-CT into oncology in
general [190] there have been several studies for head
andneckcanceraspartoftheinitialstaging[191],[192]
and during follow-up for the detection of recurrence and
second primaries [193], [194], [195]. In general, these
studies just compare PET-CT with other imaging modal-
ities. Only rarely the result of PET or PET-CT is compared
to the histopathological diagnosis or the clinical course
of untreated PET-CT-positive lesions is evaluated, e.g. if
these lesions lead to locoregional recurrence. For ex-
ample, there was a consensusof PET-CT and histopatho-
logy in only 9 out of 16 neck dissections [196]. Another
study compared PET, PET-CT, CT, and MR and showed
that PET-CT had a better accuracy than CT/MR in detect-
ingprimariesandmetastases(98%vs.86%and92%vs.
85%,respectively)[197]butstilltherewerefalse-positive
and false-negative results [198].
5 Perspectives
In summary therearethreeareasthathave thepotential
to yield an improvement of the early detection of head
and neck cancer in the near future: 1. improved analysis
of cytological specimens, 2. novel approaches to identify
tumormarkers,and3.improvedinvestigationtechniques
for the detection of altered mucosa.
5.1 Cytodiagnostic
There is a renaissance of cytodiagnostic assays in the
head and neck region recently [131]. This is due to the
novel insights into the development of cancer [86], [87],
[199], to better minimal-invasive approaches to obtain
specimens, and to improved optical (detection) systems.
In general cytopathology can be improved by the use of
cytometric techniques as this has been advocated as
“intensified cytodiagnostic” by Hanson et al. in 1989
[200]andlinedoutbyBöckingetal.in2004[201].Since
the specimen in general is analyzed on a slide as a solid
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carrier these techniques are summarized as slide-based
cytometry (SBC) [202].
A major focus is set on the determination of the DNA-
ploidy of the tumor cells. Shortly after patenting the
world’sfirstflowcytometerbyPartecinMünster,Germany
(ImpulscytophotometerIPC11)[203]theanalysisofDNA-
content of single cells was established [204]. The first
application for head and neck cancer was published in
1972 [205]. In parallel, the analysis of DNA-ploidy by
imagecytometrywasdevelopedandappliedtoheadand
neck cancer, too [206]. This lead to the identification of
DNA-ploidyasaprognosticparameteronitsownforhead
and neck cancer: most tumors are DNA-aneuploid, and
patientswithaDNA-diploidtumorhaveabetterprognosis
forboth,locoregionalmetastasesand5-year-survivalrate
[207], [208], [209], [210], [211], [212], [213].
Unlikeflowcytometrywhichneedslargeramountsofcells
obtained by tissue specimens, for SBC minimal (hypocel-
lular) specimens suffice (such as FNABs or exfoliative
cytologies). The DNA-ploidy can be determined by image
cytometry after Feulgen staining [214], [215] or by laser
scanning cytometry after fluorescent staining [216],
[217], [218] (Figure 2), both methods being adequate
[219]. The sensitivity and specificity for detecting a head
andneckcancerare79–96%and93–100%,respectively.
In addition to the DNA-ploidy, other markers can be ana-
lyzed [220]. The analysis of DNA-ploidy allows to detect
a carcinoma months before it can be identified by histo-
pathology [221]. SBC allows to reduce the proportion of
“inadequate” specimens for cytological analysis. This
technology can be applied throughout the entire upper
aerodigestive tract even in areas not accessible for con-
ventional swabs: esophagus and hypopharynx can be
screened in a cursorical manner by using sponge that is
swallowed by the patient [222].
In other areas the cytological work-up has been already
updated for its clinical use to a much better extent than
in ENT. Screening for cervical cancer and its precursors
for example in many schemes includes a variant of SBC,
such called liquid-based cytology: the specimen is ob-
tained as a suspension and dispersed on a microscopic
glass slide in a special centrifuge and analyzed automat-
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to conventional swabs where cells tend to lay in clusters
ofseverallayersandshowsubstantialvariationinfixation
and staining [224], [225]. In the follow-up of urological
tumors, a quantitative cytological analysis of specimens
obtained from voided urine using fluorescence-in-situ-
hybridization has been established [226].
SBCisleadingtoanobjectiveandquantitativehistopatho-
logical analysis even avoiding staining with exogenous
dyes at all (see 5.3.4) [227], [228], [229], [230].
5.2 Proteomics
The transition of a cell from normal to cancer includes
significantchangesintheexpressionofcellularproteins.
This includes the cancerous cell itself, but affects also
the surrounding normal cells of blood vessels, of the
connectivetissueandinfiltratinginflammatorycells.This
yieldstoachangeintheproteinscirculatingintheserum
throughoutthebody.Proteomicsintendstoidentifysingle
biomarkers or clusters of protein changes (signatures)
which allow to detect the presence or recurrence of a
cancer. It aims to help in screening, initial staging, and
follow-up, too. Proteomic based biomarkers are thought
to open the door to personalized medicine in near future
[231]. Using a plethora of different assays biomarkers
are targeted from the DNA via RNA to protein expression
on cell, tissue, and plasma level (cDNA array, oligonuc-
leotidearrays,reverse-phaseproteomicarrays,andtissue
arrays)[231].Forheadandneckcancer,therehavebeen
applications developed on protein level using surface
enhancedlaserdesorption/ionizationtime-of-flightmass
spectrometry(SELDI-TOF-MS)[232]andevaluated[142],
[233], [234]. A SELDI-TOF-MS-based classification had a
sensitivity of 82–92% and a specificity of 76–90%. As
long as biomarkers are proteins they can be bound by
antibodies. Novel techniques allow to bind a set of differ-
ent antibodies to a glass slide [235]; this approach has
already been applied for the identification of novel bio-
markers of breast cancer analyzing synchronously 387
proteins on a single array [236]. Flow cytometry can also
be used for the simultaneous analysis of several blood-
bound proteins, e.g. cytokines [237], [238].
A fusion of different novel detection assays on the one
hand and of minimal specimen requirements on the
otherhandistargetedbythe“lab-on-the-chip”-technology.
These applications could finally be less expensive than
present detection systems and are reviewed excellently
by Ziober et al. [239]. Taking saliva as the specimen,
applications cover the entire spectrum of oncology, from
screening via initial staging to detection if minimal-re-
sidual disease or recurrence.
The major problem of proteomics actually is to extract
that part of information out of the vast amount of data
whichisrelevantfortherespectiveapplication.Therefore,
following Virchow’s concept of Cellularpathologie putting
the cell as the smallest unit of life [240] the Human
Cytome Project was initiated [241]. So far, the bottom-up
concept of integrating single bits of information into one
working concept has not been successful: looking at
proteinchemistry, it tookmorethan30 years ofresearch
but still there is no way to predict the 3D-structure of
proteins based solely on their amino acid sequence. In-
stead, proteins are synthesized and then their 3D-struc-
ture is analyzed. One has to keep in mind that this is a
problemofjust23variables(i.e.,aminoacids).Obviously
it will take some time until one can construct the cellular
phenotype after analyzing the up to 20,000 genes and
theirproductsasitistriedintheHumanGenomeProject.
Besides the fact that there are novel members detected
continuously, not all “rules” of interaction between the
20,000 variables are understood and even novel “regu-
latory boards” are discovered (e.g., siRNA). Respecting
these frustrating attempts, the Human Cytome Project is
workingtop-down:takingtheknownphenotyperepresent-
ed by the cell (normal vs. ill) the obtained cell-based in-
formation is classified in a learning set and then applied
to a test set [242], [243]. This allows to predict the clin-
icalcourse(i.e.survival)ofcoloncancerwithalmost100%
accuracy [244] and to identify those patients with acute
myeloic leukemia (AML) who need maximal therapy (i.e.
stem cell transplantation) even before any therapy has
beeninitiated[245]. Thisapproachhasalsogreatpoten-
tial in drug discovery [246], [247].
For screening, at present those assays have the biggest
potential that allow to globally determine the individual
riskofcancerwith a simpletest.First,thereareanalyses
of saliva detecting its genotoxic potential (AMES-test)
[248] or the (hyper)methylation of specific sequences
within the genome [249]. Second, there are cytological
analysesofcellscontainedinthesalivainordertodetect
global changes of the genome such as micronuclei or
DNA-ploidy [250], [251]. In addition, peripheral blood
leukocytes can be analyzed for their susceptibility to
cancerogenes (using the bleomycin-test [252] or the
COMET-assays [253], [254], [255], [256], [257]). These
tests could be used for a pre-selection in a population-
based screening.
5.3 Optimized visualization
The assays discussedin 5.1 and 5.2 yield to identify indi-
viduals with a (so far undetected) head and neck cancer.
Most assays have the major drawback that they are not
able to pinpoint the exact location of the cancer in the
widefieldoftheupperaerodigestivetract.Inthefollowing
some endoscopical approaches will be discussed that
deal exactly with this problem: to highlight areas within
the mucosa with altered architecture or even single can-
cer cells.
5.3.1 Chromoendoscopy
For a long time it has been recognized that mucosa with
an altered structure shows a different behavior when
stained with exogenous dyes as compared to normal
mucosa. In 1835 the French physician Jean Guillame
Lugol described the iodine-kaliumiodine-solution named
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afterhim.Afirstreportaboutitsuseduringanesophago-
scopydatesasitslatestbackto1966[258]butitalmost
certainly was widely used earlier than that. Recently it is
re-discovered by colleagues from surgical and medical
departments for endoscopy [178], [180], [259] although
it was widely practiced in many ENT-departments as
standardprocedureaccordingtopersonalcommunication
of the author with senior members of the society. Lugol’s
staining has a sensitivity of 96% and a specificity of 63%
in identifying highly dysplastic lesions of the esophagus
[260].Duetoitsminimaltechnicalrequirements,itssafe
use, and the low prize justify its use for the investigation
of the esophagus by ENT-doctors, too. However, its appli-
cation in the oral cavity, the oro- and hypopharynx and
the larynx leads to dysesthesia and even pain, and there
havebeenwarningcommentsaboutaspiration[261], so
thatitshouldnotbeappliedfortheinvestigationofthese
anatomical regions.
Thepotentialofautofluorescencealoneorincombination
with5-ALA-inducedPPIX-fluorescencehavealreadybeen
discussed in 4.1.2 and 4.2.1. Sensitivity and specificity
for the discrimination of normal mucosa and cancer by
autofluorescence are quoted as 91% and 86%, respect-
ively, by 5-ALA-induced PPIX fluorescence as 99% and
60%, respectively, and therefore are better than with
white light (75% and 43%).
5.3.2 Optical coherence tomography
In optical coherence tomography (OCT) light with long
wavelength (>1,300 nm) is used similar to ultrasound in
order to obtain sectional views or 3D-reconstructions of
the mucosa. Similar to applications at the retina [262]
the reflected light is used to imagine thickness and
structureofthemucosawithalateralresolutionof10µm
and a depth of penetration of 2 mm. So far applications
for laryngeal mucosa have been published; especially in
non-exophytic lesions with smooth surface the mucosal
thickness and the basal membrane can be analyzed
[263], [264], [265]. Further technical modification could
allowtointegratethistechnologyintoconventionalendo-
scopes [266], [267]. Recently there has been the devel-
opment of a µOCT that has a resolution down to the
subcellular level showing a very good correlation with
conventional histological sections [268] (Figure 3). OCT
still has to be evaluated for its clinical use.
This also applies to narrow band imaging (NBI). This
technology also makes use of the reflected light which is
passedthroughadequatefilterslimitingthewavelengths
to “narrow bands” (i.e. 400–430 nm, 430–460 nm, and
485–515nm).Thisallowstobettervisualizethemicrovas-
culature within the mucosa and in deeper layers [261].
This technique has already been integrated into conven-
tional endoscopes and can be used for the detection of
superficial mucosal changes in the oral cavity and the
oro- and hypopharynx [269].
5.3.3 Confocal endomicroscopy
Another step to in-vivo-histology is offered by confocal
laserscanningmicroscopy(cLSM).Thistechnologyyields
a lateral resolution of 0.5–1 µm, an axial resolution of
3–5 µm, and a maximal depth of 200–500 µm [270].
This allows to gain most of the information that is ob-
tained by conventional routine histopathology in order to
analyzetissueandtodiscriminatebenignfrommalignant
lesions: size and configuration of nuclei, morphology of
thechromatin,prominentnucleoli,mitoses,andtheratio
nucleus:plasma. Based on microfabrication [271] the tip
ofconventionalendoscopescanbefittedwithaminiatur-
ized cLSM-objective and to mount it to 50–100,000 op-
tical fibers; this allows confocal endomicroscopy [272].
First applications have been described for colon cancer
highlighting the optical properties impressively [273],
[274] (Figure 4). Shortly after that first applications for
laryngeal endoscopy have been published [275]: the re-
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sected mucosa in this paper actually has been studied
usingconventionaluprightconfocallaserscanningmicro-
scopy.However,inprinciplethesteptolaryngealconfocal
endoscopy has been made.
In conclusion, these techniques (optical coherence
tomography, confocal endomicroscopy) will yield blood-
less, optical in-vivo sections. However, as long as there
are no automatic algorithms analyzing the images there
will be a reduced information obtained by these sections
just as it is the case with routine histopathology: the
sections have to be assessed by the observer’s eye and
his or her brain behind them. At least they are looking at
living cells in action which is not the case in pathology.
5.3.4 Hyperspectral imaging
Thecellularfunctioncanbebetterassessedbyanalyzing
the electromagnetic spectrum. This approach has been
used by geoscienticts when analyzing and classifying
satellite images. “Spectral imaging” is defined as analyz-
ing the entire spectrum from infrared to ultraviolet for
every single pixel of an image. This generates an “image
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cube”, i.e. a stack of 2-dimensional intensity maps for
single wavelengths [276] (Figure 5). This allows to
identify optical signatures specific for malignant cells.
The term “spectral histochemistry” was coined 1998
[277]andpointsoutthepossibilitytoanalyzetissuenon-
invasively:anyalteredcellularfunctionyieldstoachange
of the contents of the cellular and extracellular constitu-
ents. This in turn changes the spectrum of the reflected
light.Thepotentialofthistechnologyhasbeendescribed
first for the diagnosis of malignant melanoma [278],
[279]. Another very practical application is the determin-
ation of the Hb-content non-invasively spectroscopically
by analyzing the conjunctiva within 1 second [280].
On tissue sections hyperspectral imaging allows to
quantitativelyanalyzetheexpressionofareceptor[281].
Thiscanbeachievedevenwithouttheuseofanyexogen-
ous dyes [282]. A pilot study of the use of hyperspectral
imaging in mucosal lesions of the oral cavity showed a
sensitivityandaspecificityof96%forthein-vivodetection
of normal versus dys- or neoplastic mucosa [283]. The
group of Dan Farkas showed that the combination of
different optical techniques [reflectance, fluorescence,
scattering,2-photon-excitation)yieldevenbettersensitiv-
ity and specificity [284]. They have developed a suitable
hyperspectral endoscopy, too [285].
5.3.5 In vivo-cytometry & molecular imaging
The ultimate analytical tool is a technology that does not
take a specimen at all and avoids invasive means. Such
atechnologyisinvivo-cytometry.Modelssofarhavebeen
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several modifications for murine models have been de-
veloped [287], [288], [289], [290]. In animal there have
been further assays analyzing circulating tumor cells
[291] and tissue analyses [292].
Novel concepts go even further in the animal model
making use of the entire plethora of available technolo-
gies in order to analyze cancer cells at their different
characteristics(proliferation,infiltration,metastasis)non-
invasively in the living organism [293]. Genetically en-
codedreportersystemsleadingtotriggeredfluorescence
allow to track a single cells or a cluster of cells through
thebodyofthetestanimal.Thenumberofavailabledyes
is steadily increasing and is ever better fitting the special
needsofthevariousapplications[294],[295].Atpresent
the aim is to tag single genome sequences and to make
them work visibly in the living animal in order to better
understandprocessessuchasmetastasis[296].Another
applicationisthefluorescencebaseddetectionofsentinel
lymph nodes [297]. Instead of turning the cell to express
the fluorochrome and hence light up the cells can alter-
natively be tagged with a fluorochrome directly; for this
purpose quantum dots have proven beneficial [298].
However, some obstacles have to be taken until this can
beappliedtohumanpatients;forexample,quantumdots
set heavy metal ions free yielding toxic effects so that
they cannot applied in medicine yet.
6 Concluding remarks
Wehavetoanticipatethatmostpatientsatrisk(smokers)
also in future will not attend screening programs as long
as they have no symptoms. Global test that help to
identifyasymptomaticcancerpatientsusingsalivaspeci-
menscouldhowevereasilybeusedinoccupationalhealth
screening of risk population (“blue collar workers”).
The most powerful tools in early detection of head and
neckcancerstillwillbetakingathoroughhistoryconcern-
ing signs and symptoms and risk factors including previ-
ousheadandneckcancer,andacloselookduringexam-
ination. The clinician’s eye already has some support by
optical tools that guide to altered mucosal areas such as
chromoendoscopyandautofluorescence.Uptonowthere
is a lack of a tool that can be used throughout the entire
upper aerodigestive tract. Hyperspectral imaging seems
to be very promising in order to highlight suspicious le-
sionswhichthencanbeinvestigatedbyopticalsectioning
usingopticalcoherencetomographyorconfocalendomi-
croscopy. These applications yield a lateral resolution in
the subcellular dimension.
Pilotstudieshaveshownthatpatientswithdetectedareas
of altered mucosa as well as solid tumors of salivary
glands benefit from an intensified cytodiagnostic work-
up: computer-based, quantitative, and objective tech-
niquesallowtoanalyzeespeciallyhypocellularspecimens
better than the naked eye. On the horizon already tech-
niques for quantitative histology can be seen which will
rapidly gain importance due to the increasingdiversity of
therapy strategies for a growing number of tumors (anti-
body-based, “targeted” therapy).
Novel technologies might in future allow to perform in
vivo-cytometryandmolecularimagingwithrevolutionizing
applications for both, therapy and diagnostics, of malig-
nancies. However, these approaches are at the test ani-
mal level at present.
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